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ABSTRACT (250 words) 
Recent studies have shown that cancer risk related to overweight and obesity is mediated by time and 
might be better approximated by using life years lived with excess weight. In this study we aimed to 
assess the impact of overweight duration and intensity in older adults on the risk of developing different 
forms of cancer. Study participants from seven European and one US cohort study with two or more 
weight assessments during follow-up were included (n=329,595). Trajectories of body mass index (BMI) 
across ages were estimated using a quadratic growth model; overweight duration (BMI≥25) and 
cumulative weighted overweight years were calculated. In multivariate Cox models and random effects 
analyses, a longer duration of overweight was significantly associated with the incidence of obesity-
related cancer (overall Hazard Ratio (HR) per 10-yr increment: 1.39; 95%CI: 1.13-1.64), but also 
increased the risk of postmenopausal breast and colorectal cancer. Additionally accounting for the 
degree of overweight further increased the risk of obesity-related cancer. Risks associated with a longer 
overweight duration were higher in men than in women and were attenuated by smoking. For 
postmenopausal breast cancer, increased risks were confined to women who never used hormone 
therapy. Overall, 8.5% of all obesity-related cancers could be attributed to overweight at any age (10.7% 
in never smokers). These findings provide further insights into the role of overweight duration in the 
etiology of cancer and indicate that weight control is relevant at all ages. This knowledge is vital for the 
development of effective and targeted cancer prevention strategies.  
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INTRODUCTION 
Obesity has emerged as one of the most prevalent risk factors for non-communicable diseases and is still 
on the rise in many populations.(1) Currently about 69% of all US adults are considered overweight or 
obese (body mass index, BMI ≥25 kg/m2) and 36% obese (BMI ≥30 kg/m2), making it one of the countries 
with the highest prevalence of obesity in the world.(2,3) Even though the level of obesity has been 
catching up in Western Europe over the past two decades, obesity prevalence is still presently lower 
than in North America, 20% in 2008.(2) In addition, overweight has become a growing problem 
specifically in the elderly, the fastest growing population segment in most high-income countries. For 
example, both in Europe and in the US, women aged 60 and above are more likely to be overweight or 
obese than any other age group. (3,4)  
These developments have come at the cost of parallel rises in obesity-related morbidities, health care 
expenditures and mortality, most notably from cardio-vascular diseases and cancer.(5) In 2012, nearly 
half a million cancer cases globally were attributable to high BMI; more than half of this burden occurred 
in higher-income regions, most notably in Europe and Northern America.(6) These disparities across 
countries and regions not only reflect varying levels of obesity, but also differences in the strength of the 
cancer-obesity association between populations and in the prevalence and distribution of other risk 
factors modifying the association, such as smoking, diabetes and the use of hormone therapy (HT).(7) 
Although the link between obesity and cancer is well-documented(7), most studies investigating this 
association are based on single measurements of height and weight at one point in life and evidence on 
the cumulative effects of overweight during the life course on disease risk remains scarce. Yet recent 
studies have shown that obesity duration is an important and independent predictor of type 2 
diabetes(8), cardio-vascular disease(9) and all-cause mortality(10). Given that a longer exposure to 
overweight increases the risk and severity of insulin resistance, chronic inflammation, oxidative DNA 
damage and alterations in endogenous hormone levels (11) – all of which are thought to be cancer 
promotive – overweight duration may be an important, but also yet understudied, predictor of the risk 
of cancer development. 
In this study, we assessed the impact of overweight duration and intensity on cancer risk in more than 
300,000 older adults in a pooled dataset of seven European and one US prospective cohort studies. In 
secondary analyses, we evaluated the effects of important effect modifiers and confounders including 
sex, smoking status, diabetes and HT.  
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MATERIALS AND METHODS 
Study design and participants 
This study uses repeated anthropometric assessments obtained from seven European (EPIC Elderly 
Denmark, Greece, Netherlands, and Spain; ESTHER, Germany; PRIME Belfast, Northern Ireland; Tromsø, 
Norway) and one American cohort study (NIH AARP), pooled as part of the Consortium of Health and 
Aging: Network of Cohorts in Europe and the United States (CHANCES, www.chancesfp7.eu). A selection 
of the cohorts’ key characteristics is shown in Table 1. Additional information on the individual cohorts 
has been described elsewhere.(12) All CHANCES cohort studies are conducted in accordance with the 
Declaration of Helsinki. For each study, investigators satisfied the local requirements for ethical 
research, including obtaining informed consent from participants.  
Study participants were required to have at least two valid BMI assessments during follow-up, including 
baseline and excluding assessments after or in the year preceding cancer diagnosis. For NIH AARP, 
participants with a retrospective self-reported BMI at age 50 and height and weight assessments at 
baseline were included. As this study is based on repeated assessments, participants with unknown date 
of re-contact were excluded (29,667, 4.7% of total). BMI values below 15 kg/m2 and above 45 kg/m2 
were considered highly unlikely and considered as missing. Patients with a history of cancer and/or 
missing data on either smoking or physical activity status were excluded (17,894, 2.8% of total). The 
derivation of the final number of included persons by study is portrayed in Figure 1.   
Outcomes 
Analyses were conducted for specific cancer sites where convincing evidence of a positive association 
with excess BMI was reported.(7,13) We examined invasive breast cancer (ICD-10 C50) at 
postmenopausal ages, colorectal cancer (C18-21), as well as a combined obesity-related cancer category 
that also included cancer of the pancreas (C25), gallbladder (C23), kidney (C64) and endometrium (C54). 
Small numbers precluded the possibility to perform separate analyses of each obesity-related cancer 
site.  
Exposure variables 
Overweight was defined as having a BMI above 25 kg/m2. For all European studies except ESTHER, 
where only self-reported BMI was available, BMI was calculated based on measured height and weight. 
In NIH AARP, height and weight were self-reported at age 50 (retrospectively) and at baseline. While 
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two BMI assessments were available for study participants from the EPIC, NIH AARP and the PRIME 
Belfast cohorts, data from up to four time points were available from ESTHER.  
Covariates 
Baseline information on all covariates except alcohol consumption (continuous, grams/day) were 
available as categorical variables as follows: (daily) smoking status (never smoker/former 
smoker/current smoker), (vigorous) physical activity (yes/no), highest level of education (primary or 
less/more than primary but less than college or university/college or university), HT use (never/ever). 
Other information on reproductive history and diet were not consistently available in all cohorts and 
could not be taken into account in our analyses.  
Statistical analysis 
The analysis was carried out in three steps. First, a quadratic growth model with a random intercept and 
random slope was used to predict individual BMI trajectories for each study participant.(14,15) This 
model was developed and adjusted in a step-wise manner by adding study, sex, smoking status, physical 
activity and an interaction term for study and contact age to the fixed effects part of the model. The 
obtained predicted BMI values for all ages between study entry and study exit were then used to 
estimate overweight (BMI≥25) duration in years. Weighted cumulative overweight years (OWY) were 
computed by multiplying the duration of overweight in years by the difference (in BMI units) above 
normal BMI (BMI≥25) for each increment of age. This measure takes into account the degree of 
overweight over time and is comparable to pack-years in relation to tobacco smoking. Overweight 
duration was assessed per 10-year increment and cumulative OWY per 100 units.  
Secondly, Cox proportional hazard models with age as time metric were used to estimate hazard ratios 
(HR) and 95% confidence limits (CI) to describe the relation between overweight duration, cumulative 
OWY and the risk of developing cancer. Overweight duration and cumulative OWY were treated as 
continuous, time-dependent covariates in the model. Subjects were censored at death, lost to follow-
up, any cancer excluding non-melanoma skin cancer (C44) diagnosis other than the site of interest and 
end of follow-up, whichever occurred first. For all outcomes, three models with different sets of 
adjustments were fitted. In model 1, adjustments were made for age and sex. Model 2 was additionally 
adjusted for smoking status and physical activity. In model 3, further adjustments were made for 
education and alcohol consumption. All analyses were carried out for each study separately and the 
results were then combined using random-effects meta-analysis. (16) We used three-knot cubic splines 
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to model non-linear relations between obesity duration, OWY and cancer risk. In secondary analyses, 
data from all cohorts were pooled to assess interactions in stratified analyses by sex, smoking status, HT 
use and diabetes history. 
Lastly, and based on the assumption that the association between overweight and the cancer sites 
included in our study is causal (17), population attributable fractions (PAF) and their 95% CIs were 
calculated (18,19) using the maximum likelihood method (20) and the ‘punaf’ command in Stata. PAFs 
represent the proportion of obesity-related cancer cases that could have been avoided if participants 
were never overweight during follow-up.  
All statistical analyses were performed using Stata 12. 
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RESULTS 
In total, 329 595 participants were included in this study, with 14 998 obesity-related cancer cases 
occurring during follow-up (Table 1). Study participants were recruited between 1991 and 2003, with a 
mean age at study entry ranging from 54 years in Northern Ireland (PRIME Belfast) cohort to 67 years in 
Greece (EPIC elderly). Education level (highest attained degree) was particularly high in the US (NIH 
AARP) (75% with college or university degree), while more than 85% of the Spanish participants (EPIC 
elderly) had only primary education or less. Mean BMI at baseline ranged between 25.8 kg/m2 in the 
Netherlands to 29.5 kg/m2 in Spain, where 42% of the study participants were classified as obese 
(BMI≥30). While 75% of all participants from Denmark (EPIC elderly) reported to be physically active, 
this applied to only 5% in Spain. Alcohol intake was highest in Denmark (20.2 g/d) and lowest in Norway 
(Tromsø – 3.6 g/d), in contrast with smoking, where Norway had the highest and Greece the lowest 
proportion of current daily smokers (31% and 12% respectively). Median follow-up ranged between 10.4 
years in Germany (ESTHER) and 18.0 years in Northern Ireland (PRIME Belfast). Age-standardized 
incidence rates of obesity-related cancers ranged between 319 per 100 000 person-years in the US to 29 
per 100 000 in Greece.  
In the meta-analysis of all studies, a longer duration of overweight was significantly associated with an 
increased risk of obesity-related cancer combined (Hazard Ratio (HR) per 10-yr increment: 1.39; 95%CI: 
1.13 to 1.64) and was most pronounced in the German ESTHER cohort (HR: 2.52, 95%CI: 1.80 to 3.52), 
but not statistically significant in the Spanish and Danish EPIC cohorts (Figure 2). When taking the 
degree of overweight over time into account, risks tended to be slightly more pronounced, especially in 
the US NIH AARP cohort (Figure 2), but also overall (HR per 100-unit increment in OWY: 1.47; 95%CI: 
1.15 to 1.80). While results were similar for postmenopausal breast and colorectal cancer, higher risks 
were found for other obesity-related sites, comprising cancer of the pancreas, kidney, gallbladder and 
endometrium. HRs for the association between overweight duration and cumulative OWY by cancer site 
and cohort, for the different models are presented in Supplementary Table 1. As adjustments for 
alcohol consumption and education level in model 3 only marginally altered the results of model 2, the 
latter simpler model was used when exploring dose-response relationships between increasing 
overweight duration, intensity and cancer risk. Clear associations were found for all obesity-related 
cancer sites combined, but also for breast cancer in HT non-users (Figure 3, panel A). When taking into 
account the degree of overweight over time, the risk increase became more pronounced, especially for 
other obesity-related cancers (Figure 3, panel B). This relationship was mainly driven by kidney and 
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endometrial cancer, showing exponential associations with the combination of overweight duration and 
intensity over time (Supplementary Figure 1). 
The population attributable fraction (PAF) for ever being overweight during follow-up was 8.5% (95%CI: 
6.2 to 10.7%) for obesity-related cancers combined (Table 2). PAFs were considerably higher in men 
than in women (18.7% vs 5.4%), in never smokers relative to current and past smokers and in those with 
a history of diabetes type 2. In women who never used HT, 17.9% (12.6 to 22.8%) of all breast cancers 
were attributable to ever being overweight during follow-up.  
In secondary analyses, we investigated the potential confounding effects of sex, smoking status, HT use 
and diabetes history in the pooled dataset (Supplementary Table 2). Generally, the risks associated with 
both overweight duration and cumulative OWY were higher in men than in women. After stratification 
for sex, the risk of colorectal cancer associated with a longer overweight duration and intensity (OWY) 
reached statistical significance in both men and women. Clear gradients in risk were found across 
smoking categories, indicating that the risk of obesity-related cancer due to overweight duration and/or 
cumulative OWY was highest among never smokers, intermediate among former smokers and low or 
negligible in current smokers. For breast cancer, significant effects were limited to never smokers and 
those who never used HT, with similar effect sizes for both overweight duration (HR: 1.41, 95%CI: 1.25 
to 2.58) and cumulative OWY (HR: 1.33, 95%CI: 1.15 to 1.53). Risks of obesity-related cancers were 
higher in study participants who ever reported type 2 diabetes relative to those who had no diabetes 
history, especially when the degree of overweight over time was taken into account. 
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DISCUSSION 
Based on a pooling of eight cohort studies, 300 000 participants and more than 15 000 obesity-related 
cancers, this is the first study to assess the impact of overweight duration on cancer risk in older 
populations. Overall, we found that a longer duration of overweight was significantly associated with a 
higher risk of postmenopausal breast and colorectal cancer, as well as for obesity-related cancers 
combined. Risks associated with a longer overweight duration were higher in men than in women and 
among non-smokers than in current smokers. For post-menopausal breast cancer, increased risks were 
confined to women who never used HT. When additionally taking the degree of overweight over time 
into account, risks increased even further. Overall, 8.5% of obesity-related cancers could be attributed 
to being overweight at any time point after age 50 (10.7% in never smokers).  
These findings are consistent with studies reporting associations between high BMI at one point in time 
and cancer risk (7,21) and are in line with evidence on the impact of obesity duration on other health 
outcomes, including type 2 diabetes, cardiovascular disease and all-cause mortality.(8-10) One of the 
putative underlying biological mechanisms involves changes in the metabolism of sex-steroid hormones, 
namely oestrogen, which is mainly produced by fat tissue in postmenopausal women.(22) Hence, a 
longer overweight duration increases the exposure time to elevated hormone levels, which may in turn 
increase the risk of developing cancer. In our study, we found that the increased risk of postmenopausal 
breast cancer related to a longer overweight duration was confined to women who never used HT and 
risks were similar for overweight duration and OWY. This finding suggests that exogenous oestrogen and 
hormone levels modify the association between overweight duration and postmenopausal breast 
cancer, as noted in previous studies.(23,24) 
We also noted important sex differences in the risk of developing obesity-related cancer associated with 
increasing overweight duration. Higher risks in men were mainly evident for colorectal cancer and all 
obesity-related cancers combined. This is consistent with previous studies pointing towards a stronger 
link between different measures of obesity and colorectal cancer in men, with the association much 
weaker or absent in women.(25,26) Increased waist circumference has been suggested to be a better 
predictor of colorectal cancer risk than BMI that varies markedly by sex.(26,27)  Waist circumference is a 
proxy for visceral adipose tissue, where leptin and adiponectin are predominantly secreted. Adiponectin 
is inversely correlated with body fatness, is anti-inflammatory and inhibits tumour growth in 
animals.(28) As circulating levels of adiponectin have been found to be higher in women than men, this 
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may offer an explanation for sex differences in colorectal cancer risk associated with overweight and 
obesity.(25)  
Another important confounder was smoking. We found that never smokers were at a higher risk of 
obesity-related cancer with increasing overweight duration relative to current smokers. This association 
was more pronounced when the degree of overweight was taken into account, and is supported by 
previous findings on the role of smoking in the obesity-cancer pathway. (7,29) Other factors such as 
hormones and circulating levels of DNA adducts have been suggested to contribute to lower risks of 
obesity-related cancers observed in smokers. (7,30-32) In contrast, history of type 2 diabetes modified 
the overweight-cancer association in our study in a way that participants with a positive history had the 
greatest risk. This finding confirms previous findings on the interaction between overweight duration, 
diabetes and pancreatic cancer.(33)    
While our findings were largely consistent across studies, we generally found weaker associations in the 
US cohort when compared to the European cohorts. This may be partly explained by differences in the 
baseline characteristics between European and US study participants as well as the relative study sizes. 
In comparison with the combined European cohorts, comprising 38 563 study participants, the US NIH 
AARP cohort was much larger (291 032 participants), and hence better powered. Additionally, the 
majority of the US NIH AARP participants were highly educated and less likely to be current smokers or 
physically inactive than participants of the European cohorts, limiting the generalizability of the findings 
to the general US population. Yet, given the similar associations found across the studies and the 
general notion that the effect of obesity on cancer development should not differ between Europeans 
and North Americans, we believe that our results are valid and most likely a conservative estimate of the 
true effect. 
In this pooled analysis, we were able to include a large number of study participants from several 
European countries and the US, which enabled an assessment of the dose-response relationship 
between overweight duration and cancer risk, as well as related sensitivity analyses. However, some 
methodological considerations and limitations should be noted. In the first step of our analysis, we used 
repeated measurements and self-reports of height and weight to model BMI across ages using a growth 
curve approach. With this approach, we were able to estimate each study participant’s overweight 
trajectory and duration during follow-up. As the results from the German ESTHER study (where only self-
reported height and weight were available) were consistent with those from the other European cohorts 
(where BMI was calculated based on measured height and weight), we believe that the type of BMI 
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information has not unduly affected our overall findings. When we repeated the analyses with obesity 
(BMI≥30) duration, the associations became slightly stronger. It is however important to note that BMI 
may not be an ideal measure of body fatness since it can reflect both adiposity and muscularity and is 
limited in its ability to predict body fatness across ethnic groups and age.(34) Age-related decreases in 
height might falsely lead to an increase in BMI and with advancing age fat tissue tends to be 
redistributed towards the abdominal region.(34) Hence, it might have been more appropriate to use one 
of the measures of central obesity as a surrogate for overweight and obesity as these have been 
suggested to better predict obesity-related health outcomes when compared to BMI.(35,36) These 
measures were however not available longitudinally from the cohorts included in this study. Yet, in a 
companion paper using data from the same cohorts (except NIH-AARP), we found that the risk 
associated with a standard deviation increase in baseline BMI and waist circumference were similar for 
post-menopausal breast, colorectal and obesity-related cancers combined (Heinz Freisling, personal 
communication). 
Further limitations of our study are related to differences in study design between cohorts, including 
differences in length of follow-up, anthropometric assessment methods and their frequency, as well as 
the comparability of several variables. In order to harmonize the data and variable definitions across 
cohorts, some variables such as physical activity were only available in binary form (yes/no). Despite 
adjustment for the main confounding factors, namely smoking and physical activity, we cannot rule out 
confounding by other unmeasured factors, most importantly reproductive risk factors and diet. As these 
were not consistently available from all cohorts, we were not able to take these into account in our 
analyses.  
Lastly, it is important to acknowledge a number of methodological limitations, which we hope will 
prompt further research. In the same way that we have estimated cumulative exposure for our main 
independent variable, overweight duration, it may be surmised that the nature of the confounding or 
moderating effects of other exposures (such as smoking, alcohol intake or physical activity) might, in 
uncertain ways, depend on how their own cumulative effects have been modelled. Related to this is the 
fact that methodologists have recently debated about the correct way to model cumulative effects, 
when their effects on absolute rather than relative risk scales might differ and when more complex 
temporal patterns of exposure may not be modelled well on a proportional hazards scale. (37-39) 
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Implications and conclusions 
We report that longer overweight duration increases the risk of cancer in older adults, in both Europe 
and the US, with 8.5% of obesity-related cancers attributable to overweight at any time point after age 
50. Previous studies suggest that avoidance of weight gain, engaging in physical activity, and even small 
amounts of weight loss in the elderly may prevent adverse health consequences of obesity.(34,40) Our 
findings provide further insights into the role of overweight duration on the aetiology of cancer in older 
adults and indicate that weight control is relevant at all ages. This knowledge is vital for the 
development of effective and targeted cancer prevention strategies. Future studies should further 
investigate the specific roles of age at onset of overweight and different BMI trajectories on cancer risk.  
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FIGURE LEGENDS 
 
Figure 1. Flowchart of participant inclusion 
* information on history of cancer and cancer sequence was not available from the NIH AARP cohort  
 
Figure 2. Hazard ratios (HR)* and their 95% confidence intervals (95% CI) for overweight (BMI≥25) 
duration and weighted cumulative overweight years (OWY), by cohort and cancer site, men and women 
combined. 
* results from random-effects meta-analysis with adjustments for age, sex, smoking status, physical activity (yes/no), alcohol consumption and 
education level (Model 3) 
a breast, colorectum, pancreas, kidney, gallbladder, endometrium; bpancreas, kidney, gallbladder, endometrium 
 
 
Figure 3. Hazard ratios (HR) and their 95% confidence intervals (95%CI) for the association between (A) 
overweight (BMI≥25) duration, (B) weighted cumulative overweight years (OWY) and cancer risk, men 
and women combined 
abreast, colorectum, pancreas, kidney, gallbladder, endometrium; bpancreas, kidney, gallbladder, endometrium 
The figure shows a 3-knot spline of the relation between overweight duration and cancer risk, allowing for non-linear effects and adjusted for 
age, sex, smoking status and physical activity (Model 2). P-values are for non-linearity.  
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Table 1. Selected cohort characteristics 
EPIC-Elderly Germany 
(ESTHER) 
Northern 
Ireland (PRIME 
Belfast) 
Norway 
(Tromsø) 
USA              
(NIH AARP) Denmark Greece Netherlands Spain 
Baseline characteristics (n=6,871) (n=6,877) (n=4,149) (n=4,550) (n=8347) (n=1,920) (n=5,849) (n=291,032) 
         
Recruitment year (range) 1993-1997 1994-1999 1993-1997 1992-1996 2000-2003 1991-1994 1994-1995 1995-1997 
Mean age, in years (SD) 62.5 1.5 67.0 4.4 64.3 2.8 62.5 1.7 61.8 6.6 54.2 2.8 59.4 6.9 62.2 5.3 
Sex  
   Men 3521 51.2% 2693 39.2% 154 3.7% 1931 42.4% 3784 45.3% 1920 100.0% 2736 46.8% 173065 59.5% 
   Women 3350 48.8% 4184 60.8% 3995 96.3% 2619 57.6% 4563 54.7% 0 0.0% 3113 53.2% 117967 40.5% 
Education 
   Low (primary or less) 2451 35.7% 6281 91.3% 1279 30.8% 3899 85.7% 6025 72.2% 15 0.8% 2999 51.3% 1391 0.5% 
   Medium (more than primary but less than college) 3040 44.2% 379 5.5% 2364 57.0% 317 7.0% 1736 20.8% 1655 86.2% 1710 29.2% 64972 22.3% 
   High (college or university) 1366 19.9% 200 2.9% 503 12.1% 284 6.2% 412 4.9% 250 13.0% 1108 18.9% 218582 75.1% 
   Missing 14 0.2% 17 0.2% 3 0.1% 50 1.1% 174 2.1% 0 0.0% 32 0.5% 6087 2.1% 
Mean BMI at baseline (SD) 26.1 3.8 29.3 4.3 25.8 3.9 29.5 4.0 27.6 4.2 26.1 3.2 26.1 3.7 26.8 4.5 
   Underweight (BMI < 18.5) 35 0.5% 18 0.3% 45 1.1% 4 0.1% 33 0.4% 8 0.4% 43 0.7% 2448 0.8% 
   Normal weight (BMI ≥ 18.5 & BMI < 25) 2819 41.0% 1062 15.4% 1891 45.6% 491 10.8% 2268 27.2% 717 37.3% 2352 40.2% 105200 36.1% 
   Overweight (BMI ≥ 25 & BMI < 30) 3096 45.1% 2997 43.6% 1674 40.3% 2151 47.3% 3953 47.4% 980 51.0% 2634 45.0% 123553 42.5% 
   Obese (BMI ≥ 30) 921 13.4% 2800 40.7% 539 13.0% 1904 41.8% 2093 25.1% 215 11.2% 820 14.0% 59831 20.6% 
Vigorous physical activitya 
   No 1742 25.4% 5418 78.8% 1669 40.2% 4308 94.7% 4678 56.0% 1668 86.9% 3526 60.3% 150884 51.8% 
   Yes 5129 74.6% 1459 21.2% 2480 59.8% 242 5.3% 3669 44.0% 252 13.1% 2323 39.7% 140148 48.2% 
Alcohol intake  
(average daily consumption in grams) 20.2 7.4 7.8 13.0 6.8 20 3.6 13.3 
   N missing 0 0.0% 0 0.0% 0 0.0% 0 0.0% 664 8.0% 0 0.0% 1082 18.5% 0 0.0% 
Smoking statusa 
   Never daily smoker 2293 33.4% 4830 70.2% 2002 48.3% 3095 68.0% 4188 50.2% 792 41.3% 1935 33.1% 106553 36.6% 
   Former daily smoker 2650 38.6% 1257 18.3% 1482 35.7% 722 15.9% 2771 33.2% 637 33.2% 2107 36.0% 151257 52.0% 
   Current daily smoker 1928 28.1% 790 11.5% 665 16.0% 733 16.1% 1388 16.6% 491 25.6% 1807 30.9% 33222 11.4% 
Hormone therapy useb 
   Ever 1686 50.3% 0 0.0% 3299 82.6% 2310 88.2% 1965 43.1% n/a 1475 47.4% 52024 44.1% 
   Never 1564 46.7% 0 0.0% 692 17.3% 288 11.0% 2287 50.1% n/a 873 28.0% 65943 55.9% 
   Missing 100 3.0% 4184 100.0% 4 0.1% 21 0.8% 311 6.8% n/a 765 24.6% 0 0.0% 
Self-reported or documented diabetes type 2 
   No 6429 93.6% 5924 86.1% 3986 96.1% 4026 88.5% n/a n/a n/a 266620 91.6% 
   Yes 143 2.1% 944 13.7% 159 3.8% 515 11.3% n/a n/a n/a 24412 8.4% 
   Missing 299 4.4% 9 0.1% 4 0.1% 9 0.2% n/a n/a n/a 0 0.0% 
Median follow-up time (years) 11.9 11.5 13.2 13.4 10.4 18.0 15.9 10.5 
N cancers cases (N/incidence ratec per 100 000) 734 340 403 483 845 256 722 53108 
   N breast cancer (age>50, women only) 110 42.4 21 9.3 109 57.0 42 21.4 120 86.0 0 0.0 64 39.1 5905 152.9 
   N colorectal cancer 94 37.4 37 10.1 77 39.3 66 35.1 110 67.8 40 75.3 112 53.9 4470 93.5 
   N obesity-relatedd 253 99.2 86 29.2 226 116.6 153 78.8 313 208.0 52 93.6 205 107.6 13710 318.8 
    
aparticipants with missing information on physical activity and smoking status were excluded 
bwomen only 
cage-standardized to the World standard population  
dbreast, colorectal, pancreas, kidney, gallbladder, endometrium 
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 Table 2. Population attributable fractions (PAF) of ever being overweight (body mass index >= 25kg/m2)  and cancer risk 
Obesity-related 
cancersa Breast cancer Colorectal cancer 
Other obesity-
related cancersb 
% ever 
overweight PAF (95% CI) PAF (95% CI) PAF (95% CI) PAF (95% CI) 
                  
Overall 68.6% 8.5% (6.2-10.7) 9.6% (5.3-13.8) 23.9% (19.4-28.2) 
   Men 75.0% 18.7% (14.1-23.1) 13.3% (7.3-18.9) 28.3% (20.9-35.1) 
   Women 60.0% 5.4% (2.9-7.8) * * * * 20.4% (14.8-25.7) 
   Current daily smoker 59.1% * * * * * * * * 
   Former daily smoker 72.2% 8.6% (5.1-12.0) * * 8.7% (2.2-14.8) 27.0% (20.0-33.3) 
   Never daily smoker 67.1% 10.7% (7.2-14.1) * * 15.2% (8.0-21.8) 25.7% (18.5-32.2) 
   Diabetes ever 85.8% 17.2% (3.7-28.7) * * * * 52.8% (31.8-67.3) 
   Diabetes never 66.7% 7.0% (4.7-9.3) * * 8.6% (4.0-13.0) 20.5% (15.7-25.0) 
   HRT ever users 54.7% * * * * * * * * 
   HRT never users 63.7% 17.1% (13.2-20.8) 17.9% (12.6-22.8) * * 32.3% (24.3-39.5) 
abreast, colorectum, pancreas, kidney, gallbladder, endometrium; bpancreas, kidney, gallbladder, endometrium 
* PAF not calculated because HR statistically non-significant. 
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